These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 32161197)

  • 1. Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease.
    Luukkonen PK; Tukiainen T; Juuti A; Sammalkorpi H; Haridas PAN; Niemelä O; Arola J; Orho-Melander M; Hakkarainen A; Kovanen PT; Dwivedi O; Groop L; Hodson L; Gastaldelli A; Hyötyläinen T; Orešič M; Yki-Järvinen H
    JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32161197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
    Wang P; Wu CX; Li Y; Shen N
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8997-9007. PubMed ID: 32964989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.
    Ma Y; Belyaeva OV; Brown PM; Fujita K; Valles K; Karki S; de Boer YS; Koh C; Chen Y; Du X; Handelman SK; Chen V; Speliotes EK; Nestlerode C; Thomas E; Kleiner DE; Zmuda JM; Sanyal AJ; ; Kedishvili NY; Liang TJ; Rotman Y
    Hepatology; 2019 Apr; 69(4):1504-1519. PubMed ID: 30415504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease.
    Pirola CJ; Garaycoechea M; Flichman D; Arrese M; San Martino J; Gazzi C; Castaño GO; Sookoian S
    J Lipid Res; 2019 Jan; 60(1):176-185. PubMed ID: 30323112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rs72613567: TA Variant in the Hydroxysteroid 17-beta Dehydrogenase 13 Gene Reduces Liver Damage in Obese Children.
    Di Sessa A; Umano GR; Cirillo G; Marzuillo P; Arienzo MR; Pedullà M; Miraglia Del Giudice E
    J Pediatr Gastroenterol Nutr; 2020 Mar; 70(3):371-374. PubMed ID: 31789772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease.
    Sun DQ; Wang TY; Zheng KI; Zhang HY; Wang XD; Targher G; Byrne CD; Chen YP; Yuan WJ; Jin Y; Zheng MH
    Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1822-1831. PubMed ID: 33853719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD.
    Vilar-Gomez E; Pirola CJ; Sookoian S; Wilson LA; Liang T; Chalasani N
    Clin Transl Gastroenterol; 2021 Sep; 12(9):e00400. PubMed ID: 34506332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation of 17β-hydroxysteroid dehydrogenase 13 at serine 33 attenuates nonalcoholic fatty liver disease in mice.
    Su W; Wu S; Yang Y; Guo Y; Zhang H; Su J; Chen L; Mao Z; Lan R; Cao R; Wang C; Xu H; Zhang C; Li S; Gao M; Chen X; Zheng Z; Wang B; Liu Y; Liu Z; Wang Z; Liu B; Fan X; Zhang X; Guan Y
    Nat Commun; 2022 Nov; 13(1):6577. PubMed ID: 36323699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of
    Luukkonen PK; Sakuma I; Gaspar RC; Mooring M; Nasiri A; Kahn M; Zhang XM; Zhang D; Sammalkorpi H; Penttilä AK; Orho-Melander M; Arola J; Juuti A; Zhang X; Yimlamai D; Yki-Järvinen H; Petersen KF; Shulman GI
    Proc Natl Acad Sci U S A; 2023 Jan; 120(4):e2217543120. PubMed ID: 36669104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.
    Yang J; Trépo E; Nahon P; Cao Q; Moreno C; Letouzé E; Imbeaud S; Bayard Q; Gustot T; Deviere J; Bioulac-Sage P; Calderaro J; Ganne-Carrié N; Laurent A; Blanc JF; Guyot E; Sutton A; Ziol M; Zucman-Rossi J; Nault JC
    Hepatology; 2019 Jul; 70(1):231-240. PubMed ID: 30908678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of a Loss-of-Function Variant in
    Gil-Gómez A; Rojas Á; García-Lozano MR; Muñoz-Hernández R; Gallego-Durán R; Maya-Miles D; Montero-Vallejo R; Gato S; Gallego J; Francés R; Soriano G; Ampuero J; Romero-Gómez M
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension.
    Scheiner B; Stättermayer AF; Schwabl P; Bucsics T; Paternostro R; Bauer D; Simbrunner B; Schmidt R; Marculescu R; Ferlitsch A; Peck-Radosavljevic M; Pinter M; Trauner M; Reiberger T; Ferenci P; Mandorfer M
    Liver Int; 2020 Feb; 40(2):393-404. PubMed ID: 31967400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.
    Gellert-Kristensen H; Nordestgaard BG; Tybjaerg-Hansen A; Stender S
    Hepatology; 2020 Jan; 71(1):56-66. PubMed ID: 31155741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease.
    Luukkonen PK; Qadri S; Ahlholm N; Porthan K; Männistö V; Sammalkorpi H; Penttilä AK; Hakkarainen A; Lehtimäki TE; Gaggini M; Gastaldelli A; Ala-Korpela M; Orho-Melander M; Arola J; Juuti A; Pihlajamäki J; Hodson L; Yki-Järvinen H
    J Hepatol; 2022 Mar; 76(3):526-535. PubMed ID: 34710482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17-beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms.
    Hudert CA; Adams LA; Alisi A; Anstee QM; Crudele A; Draijer LG; Furse S; Hengstler JG; Jenkins B; Karnebeek K; Kelly DA; Koot BG; Koulman A; Meierhofer D; Melton PE; Mori TA; Snowden SG; van Mourik I; Vreugdenhil A; Wiegand S; Mann JP;
    Hepatol Commun; 2022 Aug; 6(8):1934-1948. PubMed ID: 35411667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease.
    Abul-Husn NS; Cheng X; Li AH; Xin Y; Schurmann C; Stevis P; Liu Y; Kozlitina J; Stender S; Wood GC; Stepanchick AN; Still MD; McCarthy S; O'Dushlaine C; Packer JS; Balasubramanian S; Gosalia N; Esopi D; Kim SY; Mukherjee S; Lopez AE; Fuller ED; Penn J; Chu X; Luo JZ; Mirshahi UL; Carey DJ; Still CD; Feldman MD; Small A; Damrauer SM; Rader DJ; Zambrowicz B; Olson W; Murphy AJ; Borecki IB; Shuldiner AR; Reid JG; Overton JD; Yancopoulos GD; Hobbs HH; Cohen JC; Gottesman O; Teslovich TM; Baras A; Mirshahi T; Gromada J; Dewey FE
    N Engl J Med; 2018 Mar; 378(12):1096-1106. PubMed ID: 29562163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
    Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
    J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis.
    Tang S; Zhang J; Mei TT; Zhang WY; Zheng SJ; Yu HB
    BMC Gastroenterol; 2021 Dec; 21(1):490. PubMed ID: 34930143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Patatin-Like Phospholipase Domain-Containing 3 Gene for Hepatic Lipid Content and Insulin Resistance in Diabetes.
    Zaharia OP; Strassburger K; Knebel B; Kupriyanova Y; Karusheva Y; Wolkersdorfer M; Bódis K; Markgraf DF; Burkart V; Hwang JH; Kotzka J; Al-Hasani H; Szendroedi J; Roden M;
    Diabetes Care; 2020 Sep; 43(9):2161-2168. PubMed ID: 32910776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes.
    Markova M; Pivovarova O; Hornemann S; Sucher S; Frahnow T; Wegner K; Machann J; Petzke KJ; Hierholzer J; Lichtinghagen R; Herder C; Carstensen-Kirberg M; Roden M; Rudovich N; Klaus S; Thomann R; Schneeweiss R; Rohn S; Pfeiffer AF
    Gastroenterology; 2017 Feb; 152(3):571-585.e8. PubMed ID: 27765690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.